Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4010790 | 0.98 | LMNA (0.50) | SIGMAR1LMNAHRH3MAPT | |
| SCHEMBL2905469 | 0.98 | SIGMAR1 (0.51) | SIGMAR1LMNAHRH3MAPT | |
| SCHEMBL2905192 | 0.96 | LMNA (0.52) | SIGMAR1LMNAHRH3MAPT | |
| SCHEMBL10594659 | 0.91 | SIGMAR1 (0.43) | SIGMAR1LMNAHRH3 | |
| Bromide SCHEMBL10340648 | 0.89 | SIGMAR1 (0.43) | SIGMAR1LMNAHRH3 | |
| SCHEMBL9290829 | 0.87 | LMNA (0.62) | SIGMAR1LMNAHRH3MAPT | |
| SCHEMBL9290890 | 0.85 | LMNA (0.66) | SIGMAR1LMNAHRH3MAPT | |
| SCHEMBL9290957 | 0.85 | LMNA (0.66) | SIGMAR1LMNAHRH3MAPT | |
| SCHEMBL9290790 | 0.85 | LMNA (0.66) | SIGMAR1LMNAHRH3MAPT | |
| SCHEMBL5924357 | 0.84 | SIGMAR1 (0.40) | SIGMAR1LMNAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CYP11B2, IL5, TBXA2R | SIGMAR1 511/4885LMNA 3882/4885HRH3 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.